Compare Jones Lang LaSalle Inc (JLL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Novartis AG — how do they compare? Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B), while Novartis AG trades at $152.4 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.7× Jones Lang LaSalle Inc's market cap, and Novartis AG pays a 3.07% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | NVS | |
|---|---|---|
Market Cap | $16.72B | $295.37B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $168.62 |
52-Week Low | $280.16 | $119.31 |
Enterprise Value | $19.48B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
